Last updated on July 2019

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.


Brief description of study

The purpose of this study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7, 8 and 9) and MEDI4736 in combination with olaparib and bevacizumab (module 6 and 10). It will also examine what happens to the study drugs in the body and investigate how well the combination between MEDI4736, olaparib and bevacizumab is tolerated.

Detailed Study Description

This is a phase I/II open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK) and antitumor activity of MEDI4736 in combination with olaparib in patients with advanced solid tumors, selected based on a rationale for response to olaparib.

Patients will be poly (adenosine diphosphate-ribose) polymerase (PARP)-inhibitor and immunotherapy (IMT)-nave (defined as no prior exposure to PARP inhibitors or IMT, including, but not limited to, other anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], anti-programmed cell death 1 [PD-1], anti-programmed death-ligand 1 [PD-L1] monoclonal antibodies, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).

The 4 initial stage cohorts (Modules 1 to 4) include patients with relapsed small cell lung cancer (SCLC), germline BRCA mutated (gBRCAm) metastatic human epidermal growth factor receptor 2 (HER2)-negative breast cancer, gBRCAm platinum-sensitive relapsed ovarian cancer, and gastric cancer. Enrollment for these cohorts has been completed.

Second stage cohorts (Modules 5 to 7) will include patients with relapsed BRCAm platinum-sensitive relapsed ovarian cancer and non BRCAm platinum-sensitive relapsed ovarian cancer.

Third stage cohorts (Modules 8 to 10) will include patients with HER2-negative, BRCAm breast cancer (Module 8), HER2 negative, non BRCAm, Homologous Recombination Repair gene mutated (HRRm) breast cancer (Module 9) and non BRCAm, non HRRm triple negative breast cancer (TNBC) breast cancer (Module 10).

Clinical Study Identifier: NCT02734004

Find a site near you

Start Over

Research Site

Scottsdale, AZ United States
  Connect »

Research Site

Newnan, GA United States
  Connect »

Research Site

Towson, MD United States
  Connect »

Research Site

Boston, MA United States
  Connect »

Research Site

Novi, MI United States
  Connect »

Research Site

Saint Louis, MO United States
  Connect »

Research Site

Hilliard, OH United States
  Connect »

Research Site

Philadelphia, PA United States
  Connect »

Research Site

San Antonio, TX United States
  Connect »

Research Site

Milwaukee, WI United States
  Connect »

Research Site

Bordeaux Cedex, France
  Connect »

Research Site

Clermont-ferrand, France
  Connect »

Research Site

Lille Cedex, France
  Connect »

Research Site

Marseille CEDEX 5, France
  Connect »

Research Site

Nantes Cedex 02, France
  Connect »

Research Site

Pierre Benite Cedex, France
  Connect »

Research Site

Toulouse Cedex 9, France
  Connect »

Research Site

Villejuif, France
  Connect »

Research Site

Jerusalem, Israel
  Connect »

Research Site

Petah Tikva, Israel
  Connect »

Research Site

Ramat Gan, Israel
  Connect »

Research Site

Tel Aviv, Israel
  Connect »

Research Site

Goyang-si, Korea, Republic of
  Connect »

Research Site

Seongnam-si, Korea, Republic of
  Connect »

Research Site

Seoul, Korea, Republic of
  Connect »

Research Site

Amsterdam, Netherlands
  Connect »

Research Site

Maastricht, Netherlands
  Connect »

Research Site

Nijmegen, Netherlands
  Connect »

Research Site

Rotterdam, Netherlands
  Connect »

Research Site

Utrecht, Netherlands
  Connect »

Research Site

Chur, Switzerland
  Connect »

Research Site

Lausanne, Switzerland
  Connect »

Research Site

Cambridge, United Kingdom
  Connect »

Research Site

Dundee, United Kingdom
  Connect »

Research Site

Glasgow, United Kingdom
  Connect »

Research Site

Greater London, United Kingdom
  Connect »

Research Site

London, United Kingdom
  Connect »

Research Site

Manchester, United Kingdom
  Connect »

Research Site

Newcastle Upon Tyne, United Kingdom
  Connect »

Research Site

Sutton, United Kingdom
  Connect »

Research Site

Detroit, MI United States
  Connect »

Research Site

Caen Cedex 05, France
  Connect »

Research Site

Clermont Ferrand cedex 01, France
  Connect »

Research Site

Dijon cedex, France
  Connect »

Research Site

Paris cedex 14, France
  Connect »

Research Site

Pierre Benit Cedex, France
  Connect »

Research Site

Villejuif Cedex, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.